ondasdechoque.org
PT-BR

Shockwaves for chronic low-back pain: short-term pooled results · Review · 2021

Does shockwave help long-lasting low-back pain?

In this review of 10 trials (455 people in the pain results), back pain eased more with shockwave than with comparison treatments at about one month. By three months, pain results were closer between the groups. Everyday disability improved more with shockwave at one and three months.

Helped more than comparison treatments at 1 month
trials
10
people in the pain results
455
shockwave sessions per course
3–12

Good to know: Trials used different devices and 3 to 12 sessions, compared with sham, exercise, medicines, injections or other therapies.

Yue L, Sun MS, Chen H, et al. BioMed Research International, 2021 · Read the paper ↗

How this study worked

10 studies455 peopleOne answer
A review gathers earlier studies to answer one question.

What happened

studies
10
people
455
Compared with
Sham shockwave, medicines, exercise, trigger-point injections, thermomagnetic therapy or hands-on trigger-point therapy, depending on the trial

Low-back pain compared with other treatments

Standardised difference across pain scales · below zero means less pain with shockwave

Across 10 trials, pain was lower with shockwave at about one month. At three months (4 trials), the gap was smaller and less certain.
Show the numbers
Difference (standardised difference (no units))likely range
Pain at 1 month−0.81−1.21 to −0.42
Pain at 3 months−0.39−0.97 to 0.19

What the trials used

Regimens
Focused and radial devices, sometimes combined with exercise, medications or manual treatment, used heterogeneous schedules. Reported energy densities were generally 0.10–0.18 mJ/mm² and courses 3–12 sessions; not every study reported all parameters. These are descriptions, not an established optimal prescription.

Who took part

455 adults, mostly young and middle-aged (average ages 29 to 56), with low-back pain for over three months from various causes.

Side effects

Some people had pain during treatment. No serious side effects were reported, but only about half the trials checked for them.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

The pain analysis included 455 participants, mostly young and middle-aged adults with pain longer than three months. Trials mixed nonspecific, myofascial, postpartum and disc-related presentations; mean ages ranged 29.2–55.8 years.

Pain2 reported outcomes
01
Assessment nearest 1 month from baseline

Pain

Pain Standard deviation units

SMD-0.81CI 95% -1.21 to -0.42

ESWT versus heterogeneous comparators

10 studies · 455 participants in this estimate · I²=74%

-1.4Equal results 00.1

Pain favored ESWT at one month: SMD −0.81 (95% CI −1.21 to −0.42; I² = 74%), low certainty. At three months pain was inconclusive: −0.39 (−0.97 to 0.19), very low certainty. Disability estimates favored ESWT at one month −1.45 (−2.68 to −0.22; very low certainty) and three months −0.69 (−1.08 to −0.31; moderate certainty). These standardized effects are not points on a 0–10 pain scale.

Analysis details and source

Small heterogeneous trials, limited blinding and short observation reduce confidence. Forest plots visibly contain sign inconsistencies: Walewicz pain one-month and ODI one-month estimates, and Taheri pain three-month estimate, conflict with their plotted direction; Figure 4 omits the minus before the lower pooled ODI confidence limit. Pooled values here follow Results text and plots, without silently correcting individual trials.

02
Assessment nearest 3 months from baseline

Pain

Pain Standard deviation units

SMD-0.39CI 95% -0.97 to 0.19

ESWT versus heterogeneous comparators

4 studies · 205 participants in this estimate · I²=74%

-1.1Equal results 00.3

Pain favored ESWT at one month: SMD −0.81 (95% CI −1.21 to −0.42; I² = 74%), low certainty. At three months pain was inconclusive: −0.39 (−0.97 to 0.19), very low certainty. Disability estimates favored ESWT at one month −1.45 (−2.68 to −0.22; very low certainty) and three months −0.69 (−1.08 to −0.31; moderate certainty). These standardized effects are not points on a 0–10 pain scale.

Analysis details and source

Small heterogeneous trials, limited blinding and short observation reduce confidence. Forest plots visibly contain sign inconsistencies: Walewicz pain one-month and ODI one-month estimates, and Taheri pain three-month estimate, conflict with their plotted direction; Figure 4 omits the minus before the lower pooled ODI confidence limit. Pooled values here follow Results text and plots, without silently correcting individual trials.

Disability2 reported outcomes
03
Assessment nearest 1 month from baseline

Disability

Disability Standard deviation units

SMD-1.45CI 95% -2.68 to -0.22

ESWT versus heterogeneous comparators

5 studies · 211 participants in this estimate · I²=93%

-3Equal results 00.3

Pain favored ESWT at one month: SMD −0.81 (95% CI −1.21 to −0.42; I² = 74%), low certainty. At three months pain was inconclusive: −0.39 (−0.97 to 0.19), very low certainty. Disability estimates favored ESWT at one month −1.45 (−2.68 to −0.22; very low certainty) and three months −0.69 (−1.08 to −0.31; moderate certainty). These standardized effects are not points on a 0–10 pain scale.

Analysis details and source

Small heterogeneous trials, limited blinding and short observation reduce confidence. Forest plots visibly contain sign inconsistencies: Walewicz pain one-month and ODI one-month estimates, and Taheri pain three-month estimate, conflict with their plotted direction; Figure 4 omits the minus before the lower pooled ODI confidence limit. Pooled values here follow Results text and plots, without silently correcting individual trials. Results 3.5 words its GRADE sentence as “pain intensity relief” (very low quality at month 1, moderate at month 3), but the sentence sits in the disability section, Results 3.4 already rates pain (low, very low) and Discussion 4.1 calls the 1-month disability evidence very low quality; the ratings are therefore reported here for disability.

04
Assessment nearest 3 months from baseline

Disability

Disability Standard deviation units

SMD-0.69CI 95% -1.08 to -0.31

ESWT versus heterogeneous comparators

3 studies · 114 participants in this estimate · I²=0%

-1.2Equal results 00.1

Pain favored ESWT at one month: SMD −0.81 (95% CI −1.21 to −0.42; I² = 74%), low certainty. At three months pain was inconclusive: −0.39 (−0.97 to 0.19), very low certainty. Disability estimates favored ESWT at one month −1.45 (−2.68 to −0.22; very low certainty) and three months −0.69 (−1.08 to −0.31; moderate certainty). These standardized effects are not points on a 0–10 pain scale.

Analysis details and source

Small heterogeneous trials, limited blinding and short observation reduce confidence. Forest plots visibly contain sign inconsistencies: Walewicz pain one-month and ODI one-month estimates, and Taheri pain three-month estimate, conflict with their plotted direction; Figure 4 omits the minus before the lower pooled ODI confidence limit. Pooled values here follow Results text and plots, without silently correcting individual trials. Results 3.5 words its GRADE sentence as “pain intensity relief” (very low quality at month 1, moderate at month 3), but the sentence sits in the disability section, Results 3.4 already rates pain (low, very low) and Discussion 4.1 calls the 1-month disability evidence very low quality; the ratings are therefore reported here for disability.

How treatment was delivered
Regimens

Focused and radial devices, sometimes combined with exercise, medications or manual treatment, used heterogeneous schedules. Reported energy densities were generally 0.10–0.18 mJ/mm² and courses 3–12 sessions; not every study reported all parameters. These are descriptions, not an established optimal prescription.

HARMS & TOLERABILITY

Only about half the studies assessed adverse events, with unclear methods. Some participants experienced pain during treatment; no serious events were reported, but incidence cannot be estimated. Beijing Municipal Natural Science Fund supported the review; no competing interests declared.

LIMITS OF THE ANALYSIS

Small heterogeneous trials, limited blinding and short observation reduce confidence. Forest plots visibly contain sign inconsistencies: Walewicz pain one-month and ODI one-month estimates, and Taheri pain three-month estimate, conflict with their plotted direction; Figure 4 omits the minus before the lower pooled ODI confidence limit. Pooled values here follow Results text and plots, without silently correcting individual trials.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Small heterogeneous trials, limited blinding and short observation reduce confidence. Forest plots visibly contain sign inconsistencies: Walewicz pain one-month and ODI one-month estimates, and Taheri pain three-month estimate, conflict with their plotted direction; Figure 4 omits the minus before the lower pooled ODI confidence limit. Pooled values here follow Results text and plots, without silently correcting individual trials.
Research review

Source-linked critical reading

Systematic review and random-effects meta-analysis of 10 randomized trials, searched through 30 April 2021 across databases, registries and grey literature; protocol CRD 42021250013. Risk of bias, Jadad and GRADE assessments were used.

Reading depthMaterial consulted
Technical source record

Full local PDF read; All 17 PDF pages; Methods; complete Table 1 pages 5–12; Figures 1–4; forest plots visually inspected pages 13–14; Discussion; disclosures; references; supplement descriptions

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Systematic review and random-effects meta-analysis of 10 randomized trials, searched through 30 April 2021 across databases, registries and grey literature; protocol CRD42021250013. Risk of bias, Jadad and GRADE assessments were used.

Participants and setting

The pain analysis included 455 participants, mostly young and middle-aged adults with pain longer than three months. Trials mixed nonspecific, myofascial, postpartum and disc-related presentations; mean ages ranged 29.2–55.8 years.

Treatment protocol

Focused and radial devices, sometimes combined with exercise, medications or manual treatment, used heterogeneous schedules. Reported energy densities were generally 0.10–0.18 mJ/mm² and courses 3–12 sessions; not every study reported all parameters. These are descriptions, not an established optimal prescription.

Comparison

Comparators included sham, medication, exercise, trigger-point injection, thermomagnetic therapy and manual trigger therapy. Add-on and standalone comparisons were pooled; they answer different questions.

What was measured

Pain was pooled using standardized mean differences across scales; disability used the ODI. Authors selected assessments nearest one and three months from baseline, with varying actual treatment and follow-up schedules.

Results and interpretation

Pain favored ESWT at one month: SMD −0.81 (95% CI −1.21 to −0.42; I² = 74%), low certainty. At three months pain was inconclusive: −0.39 (−0.97 to 0.19), very low certainty. Disability estimates favored ESWT at one month −1.45 (−2.68 to −0.22; very low certainty) and three months −0.69 (−1.08 to −0.31; moderate certainty). These standardized effects are not points on a 0–10 pain scale.

Harms and disclosures

Only about half the studies assessed adverse events, with unclear methods. Some participants experienced pain during treatment; no serious events were reported, but incidence cannot be estimated. Beijing Municipal Natural Science Fund supported the review; no competing interests declared.

Limitations

Small heterogeneous trials, limited blinding and short observation reduce confidence. Forest plots visibly contain sign inconsistencies: Walewicz pain one-month and ODI one-month estimates, and Taheri pain three-month estimate, conflict with their plotted direction; Figure 4 omits the minus before the lower pooled ODI confidence limit. Pooled values here follow Results text and plots, without silently correcting individual trials.

Applicability

The evidence suggests possible short-term benefit as part of care but cannot select a device, dose or subgroup. Within-group clinically important changes do not establish a clinically important incremental advantage over a comparator.

What stronger evidence needs

Future blinded trials should prespecify a primary outcome, verify raw extraction and effect direction, standardize comparators, measure harms and work participation, and extend follow-up beyond three months.

THE ORIGINAL SOURCE

Read the original article.

Extracorporeal Shockwave Therapy for Treating Chronic Low Back Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Yue L, Sun MS, Chen H, Mu GZ, Sun HL. · BioMed research international · 2021

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →